Es Cushing Pituitary Directed Medical Treatments

---
name: es-cushing-pituitary-directed-medical-treatments
description: This skill suggests pituitary-directed medical treatments (e.g., cabergoline, pasireotide) for patients with Cushing's disease who are not surgical candidates or have persistent disease after transsphenoidal surgery. Use when a CD patient cannot undergo surgery or has residual disease post-TSS; triggers include "not a surgical candidate", "persistent disease after TSS", "ongoing hypercortisolism despite prior surgery".
---

# Pituitary-Directed Medical Treatments for Patients With Cushing's Disease Who Are Not Surgical Candidates or Have Persistent Disease After TSS

## STEP 1 — Gather Information
Confirm diagnosis of Cushing's disease (ACTH-dependent, pituitary source) via biochemical testing (elevated UFC, late-night salivary cortisol, dexamethasone suppression) and pituitary MRI showing adenoma; assess surgical candidacy (comorbidities, patient preference, surgical risk); document prior TSS outcome and current UFC or late-night salivary cortisol levels; evaluate for comorbidities that affect drug choice (e.g., diabetes, hyperglycemia risk).

## STEP 2 — Rule In / Rule Out
If patient has confirmed CD and is either not a surgical candidate or has persistent/recurrent disease after TSS (elevated UFC or late-night salivary cortisol post-TSS), proceed; otherwise, consider primary surgery or other definitive therapy.

## STEP 3 — Classify or Stratify
Stratify by baseline UFC severity and comorbidities: mild hypercortisolism (UFC <2× upper limit normal) and no significant hyperglycemia risk → consider cabergoline; moderate-to-severe hypercortisolism (UFC ≥2×) or diabetes/glucose intolerance → consider pasireotide; if prior failure of one agent, consider combination therapy (e.g., cabergoline + ketoconazole) per clinician judgment.

## STEP 4 — Decide
Initiate pituitary-directed medical treatment: cabergoline 0.5–2 mg orally twice weekly (up to 7 mg/week) or pasireotide 600–900 µg subcutaneously twice daily; arrange baseline metabolic panel, glucose, ECG (QT), prolactin, liver function; schedule follow-up UFC or late-night salivary cortisol at 6–12 weeks to assess biochemical control.

## Clinical Guardrails / Mimics / Pitfalls
Monitor for hyperglycemia and glycosuria with pasireotide (check fasting glucose q1–2 weeks); assess for GI side effects, gallstones, and QT prolongation; avoid in pregnancy; do not rely solely on UFC if on metyrapone or ketoconazole due to assay interference; watch for adrenal insufficiency when normalizing cortisol; do not use as bridge without planning definitive therapy if applicable.

## Concrete Clinical Example
A 50-year-old man with CD, deemed high surgical risk due to severe cardiomyopathy, had persistent hypercortisolism after TSS (UFC 180 µg/24h, normal <45). Baseline HbA1c 6.2%. Started pasireotide 600 µg SC BID. After 8 weeks, UFC 40 µg/24h, HbA1c 6.8%; continued treatment with glucose monitoring and achieved UFC normalization at 4 months.

**Source:** Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818